Sodium-Glucose Transporter 2 Inhibitor
Part of the Healio Network
Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]
Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF
Dapagliflozin plus guideline-directed medical therapy may reduce CV death in patients with HF with improved ejection fraction by lowering risk for sudden death, researchers reported.
Intensive medication optimization cost-effective in patients hospitalized with HFrEF
PHILADELPHIA — An intensive medication optimization program for patients hospitalized with HF with reduced ejection fraction would be cost-effective, researchers reported at the American Heart Association Scientific Sessions.
In acute MI, dapagliflozin confers cardiometabolic benefit, in absence of diabetes, HF
PHILADELPHIA — In patients without diabetes or heart failure presenting with acute MI and impaired left ventricular function, dapagliflozin improved cardiometabolic outcomes compared with placebo, according to the DAPA-MI trial.
Sotagliflozin reduces CV risk in patients with LV hypertrophy without high BP
Patients with left ventricular hypertrophy without hypertension were at increased risk for CV death and HF events compared with the overall SCORED trial cohort, and sotagliflozin effectively reduced risk vs. placebo, a speaker reported.
Meta-analysis shows SGLT2 inhibitors not beneficial in treating COVID-19
A meta-analysis of three trials assessing the use of SGLT2 inhibitors for inpatients with COVID-19 showed the drug class did not reduce risk for death or other outcomes compared with usual care or placebo, but was safe.
Many patients with HFrEF eligible for quad therapy at discharge; SGLT2 inhibition lacking
Quadruple therapy after discharge was feasible for a large proportion of patients with HF reduced ejection fraction, yet few were prescribed the “four pillars” of HFrEF therapy, researchers in Italy reported.
Top news June 2023: FDA approvals, updates from NLA and more
Healio | Cardiology Today has compiled a list of the top headlines in cardiology of June 2023.
Outcomes after HF hospitalization suboptimal, perhaps due to failure to follow guidelines
Among more than 250,000 patients hospitalized for HF for the first time in four countries, more than one-quarter died within 1 year of their hospitalization, according to the EVOLUTION HF cohort study.
Meta-analysis confirms benefits of SGLT2 inhibitors in various high-risk populations
SGLT2 inhibitors reduce risk for CV death and HF events in patients with any or multiple of HF, type 2 diabetes and chronic kidney disease, according to a meta-analysis published in the Journal of the American College of Cardiology.